Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
7.20
-0.31 (-4.19%)
At close: Sep 12, 2025, 4:00 PM EDT
7.19
0.00 (-0.07%)
After-hours: Sep 12, 2025, 4:57 PM EDT
Evolus Employees
Evolus had 332 employees as of December 31, 2024. The number of employees increased by 59 or 21.61% compared to the previous year.
Employees
332
Change (1Y)
59
Growth (1Y)
21.61%
Revenue / Employee
$837,172
Profits / Employee
-$186,732
Market Cap
465.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332 | 59 | 21.61% |
| Dec 31, 2023 | 273 | 58 | 26.98% |
| Dec 31, 2022 | 215 | 48 | 28.74% |
| Dec 31, 2021 | 167 | 48 | 40.34% |
| Dec 31, 2020 | 119 | -116 | -49.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EOLS News
- 2 days ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 days ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire
- 20 days ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 25 days ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
- 5 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 6 weeks ago - Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - Business Wire